Viewing StudyNCT06418711



Ignite Creation Date: 2024-05-19 @ 5:35 PM
Last Modification Date: 2024-10-26 @ 3:29 PM
Study NCT ID: NCT06418711
Status: RECRUITING
Last Update Posted: 2024-05-17
First Post: 2024-05-08

Brief Title: ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101 Clofazimine Inhalation Suspension
Sponsor: Mannkind Corporation
Organization: Mannkind Corporation

Conditions & Keywords Data

Conditions:
Name
MAC Lung Disease
Treatment Refractory MAC Lung Disease
Mycobacterium Infections Nontuberculous
Keywords:
Name View
Lamprene View
Bronchiectasis View
NTM Nontuberculous mycobacteria View
MAC Mycobacterium avium complex View
MABSC Mycobacterium abscessus complex View
Pulmonary Nontuberculous Mycobacteria View
Respiratory Infection View
antimycobacterial activity View
antimycobacterial therapy View
MAC infections View
MAC Lung disease View
MAC pulmonary infection View
Mycobacteria View
mycobacterium View
Mycobacterium Avium Complex Infections View
Mycobacterium avium complex lung disease View
mycobacterium Infections View
Nontuberculous View
Non-tuberculous mycobacterial NTM infections View
Nontuberculous mycobacterial lung disease View
Non-tuberculous mycobacterial pulmonary disease View
NTM infection View
NTM lung disease View
NTM Pulmonary Disease View
NTM lung infection View
Pulmonary MAC disease View
Pulmonary Mycobacterium Avium Complex disease View
Treatment refractory MAC lung disease View
Treatment refractory mycobacterial lung disease View
Treatment refractory NTM lung infection View
Treatment refractory NTM pulmonary disease View
Respiratory Tract diseases View
Actinomycetales Infections View
Gram-Positive Bacterial Infections View
Bacterial Infections View
Bacterial Infections and Mycoses View
Infections View
Mycobacterium Infections Nontuberculous View
Mycobacterium avium-intracellulare Infection View
Lung diseases View
Anti-Bacterial Agents View
Anti-infective Agents View
Antitubercular Agents View
Azithromycin View
Amikacin View
Ethambutol View
Clofazimine View